BMY vs GILD: Side-by-Side Comparison
Compare Bristol-Myers Squibb Company (BMY) and Gilead Sciences Inc (GILD) side by side: market cap USD 118.71B vs USD 162.98B, P/E 16.3 vs 17.9. Financials, growth and model signals on Bullrun.
| Metric | BMY | GILD |
|---|---|---|
| Company | Bristol-Myers Squibb Company | Gilead Sciences Inc |
| Country / Exchange | United States · NYSE | United States · NASDAQ |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers-General | Drug Manufacturers-General |
| Market cap | USD 118.71B | USD 162.98B |
| P/E ratio | 16.3 | 17.9 |
| Dividend yield | 5.38% | 2.45% |
| Valuation model | 21.4% undervalued | 9.2% undervalued |
| Revenue (FY2025) | USD 48.19B | USD 29.44B |
| Revenue growth YoY | -0.2% | +2.4% |
| Net income | USD 7.05B | USD 8.51B |
| Gross margin | 71.1% | 78.8% |
| Diluted EPS | 3.46 | 6.78 |